FDA Generic Drug Review Times Drop as First-Cycle Approvals Climb in FY 2026

FDA's Office of Generic Drugs posted measurable efficiency gains through the first half of FY 2026, with mean ANDA approval times falling from 35.93 months in Q1 to 32.82 months in Q2 and median times dropping even more sharply, from 25.65 to 20.29 months. For generic manufacturers calibrating submission timelines and capacity planning, the data signal a review apparatus that is processing applications faster than it did at the start of the fiscal year. The agency's latest Generic Drugs Program Monthly and Quarterly Activities Report, published April 17, 2026, provides the underlying numbers through the end of March.

The first-cycle approval count stands at 80 through the first seven months of FY 2026 (October 2025 through April 2026), with April alone contributing 17 first-cycle approvals. Total approvals reached 337 over the same period, and first-time generic approvals totaled 36. These figures matter for plant heads and QA directors evaluating whether to pursue first-cycle readiness strategies: a growing share of applications are clearing review without a complete response letter (CRL), which reduces the cost and delay of resubmission cycles. Meanwhile, the agency issued 572 complete responses through April, and 155 ANDAs were withdrawn, including 104 that had been approved and 51 that were unapproved at the time of withdrawal.

On the submission side, FDA received 309 original ANDAs through April 2026, of which 70 were designated as complex products. Amendment volume reached 1,056, split among 332 major amendments, 347 minor amendments, and 377 unsolicited amendments. Prior approval supplement (PAS) submissions totaled 851, while changes-being-effected (CBE) supplements reached 4,496. Controlled correspondence volume was substantial at 1,846, with Level 1 correspondence accounting for 1,575 of those. For regulatory affairs leads managing post-approval change strategies under 21 CFR Part 314, the PAS and CBE volumes indicate sustained activity in lifecycle management across the industry. Notably, only one PAS refuse-to-receive was recorded for the entire period.

The pending application pipeline offers additional context for resource planning. As of the most recent monthly snapshot, 1,277 ANDAs were awaiting FDA action, while 1,833 were awaiting applicant action. Tentative approvals held steady at 585, reflecting applications that are scientifically ready but blocked by patent or exclusivity provisions under the FD&C Act. The 46 granted reclassifications of facility-based major CRLs suggest that some applicants are successfully resolving GMP-related deficiencies that previously stalled their applications, while only 2 such reclassification requests were denied. Drug master file (DMF) completeness assessments totaled 222, and 121 DMF payments were received during the period.

Tentative approval times moved in the opposite direction from full approvals: mean tentative approval times rose from 45.83 months in Q1 to 49.74 months in Q2, and median times increased from 32.15 to 33.79 months. This divergence likely reflects the distinct regulatory dynamics governing tentative approvals, where patent and exclusivity timelines rather than review efficiency drive the clock. FDA noted that all figures reflect current data at the time of posting and may change based on refreshed counts in tracking systems. The data are not intended for Congressional reporting purposes. Source: FDA Generic Drugs Program Monthly and Quarterly Activities Report, published April 17, 2026.